Question-and-Answer Session
Operator
(Operator Instructions) Your first question comes from Bruce Cranna with Leerink Swann. Please proceed.
Bruce Cranna - Leerink Swann
Good morning. Just so I'm clear on this, Chris. The guidance for the year, let's say 230 or something, earnings guidance includes some additional litigation expense due to Roche after April?
Chris Twomey
Right. So assuming if we're not able to reach a settlement we would spend, I think the total is around $2 million to $3 million for the year. And if we do settle then we have other plans for those costs. So lump it all in operating expenses.
Bruce Cranna - Leerink Swann
Then I know you guys don't like to talk about the actual accounts you're in number-wise, actual hospital accounts. But it sounds like this quarter you had maybe net adds. Is that a fair way to look at it?
Kim Blickenstaff
That's true. We did. We actually saw fewer losses than projected especially as it relates to BNP and Bixis, and new account closes exceeded losses.
Bruce Cranna - Leerink Swann
Just on the stroke side and the language in the press release with FDA, I know you probably don't want to talk a lot about that either, but you talked about regarding your anticipated submission of additional information there's already been some give and take, hasn't there? Didn't you already submit or have some additional submission? Is this like a second trounce of information?
Ken Buechler
Yes, we're in the process of continuing to analyze the data that we have. And we're continuing to work with the FDA on the submissions.
Bruce Cranna - Leerink Swann
Okay. Thank you.
Operator
Your next question comes from the line of Sean McKenna with Global Crown Capital. Please proceed.
Sean McKenna - Global Crown Capital
Hi, guys, can you hear me?
Ken Buechler
Yes.
Sean McKenna - Global Crown Capital
Questions on BNP. I know last quarter you guys had talked about what you were expecting in terms of price erosion; and, correct me if I'm wrong, I think you were saying around 5% or there was some kind of range. I was wondering where you came in relative to your expectations there?
The second part of that is, I was wondering if you could talk about how many POL accounts that you guys added?
Kim Blickenstaff
I'll take the first part on the price erosion. The guidance that we had given was around 8% to 9% for the year, price erosion. That's kind of consistent on a quarterly basis, as well. The actual numbers for the first quarter was only about a 7% decline. This would be first quarter of '06 compared to the first quarter of '05. I think the guidance at this point is around 7%, 8% year-over-year. So it's slightly better than what we had been seeing and had anticipated to continue to see. So we're pleased with that.
- To read the full transcript on Seeking Alpha, click here »
